1-甲基-1H-咪唑-2-甲酸乙酯 | 30148-21-1

• 物质功能分类: 化学试剂 - 有机试剂 - 芳烃
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-1H-咪唑-2-甲酸乙酯
• 中文别名: 1-甲基-1H-咪唑-2-甲酸甲酯；1-甲基咪唑-2-甲酸乙酯；1-甲基咪唑-2-羧酸乙酯
• 英文名称: ethyl 1-methyl-1H-imidazole-2-carboxylate
• 英文别名: 1-methyl-1H-imidazole-2-carboxylic acid ethyl ester；ethyl 1-methyl-imidazole-2-carboxylate；2-Ethoxycarbonyl-1-methyl-imidazol；ethyl 1-methylimidazole-2-carboxylate
• CAS: 30148-21-1
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD02683326
• 分子量: 154.169
• InChiKey: NOTZYDYZBOBDFE-UHFFFAOYSA-N

物化性质

• 熔点：
  29-31°C
• 沸点：
  110-111°C/ 0.5 mmHg
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二氯甲烷、乙醚、乙酸乙酯和甲醇。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  T
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于惰性气体中，避免接触空气。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Ethyl 1-methylimidazole-2-carboxylate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ethyl 1-methylimidazole-2-carboxylate
Ingredient name:
CAS number: 30148-21-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2
Molecular weight: 154.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-咪唑-2-甲酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以95%的产率得到1-甲基-1H-咪唑-2-羧酸
  参考文献：
  名称：

  1H-咪唑-2-羧酸衍生物的结构引导优化，可提供有效的 VIM 型金属-β-内酰胺酶抑制剂

  摘要：

  细菌病原体中金属-β-内酰胺酶 (MBL) 的产生是对“最后手段”碳青霉烯类抗生素产生耐药性的重要原因。仍然需要开发有效的 MBL 抑制剂来逆转革兰氏阴性菌对碳青霉烯类的耐药性。我们在此报告了 1 H的 X 射线结构引导优化- 咪唑-2-羧酸（ICA）衍生物，通过考虑如何与活性位点柔性环结合并提高对革兰氏阴性细菌的渗透。构效关系研究揭示了在 ICA 1 位适当的取代基对于实现对 B1 类 MBLs，特别是 Verona Integron 编码的 MBLs (VIMs) 的有效抑制的重要性，主要是通过与灵活的活性位点环的巧妙相互作用，如观察到的那样晶体学分析。在测试的 ICA 抑制剂中，55种与美罗培南对工程大肠杆菌菌株甚至难治的临床分离的铜绿假单胞菌具有最强的协同抗菌活性生产 VIM-2 MBL。处理后细菌细胞的形态和内部结构变化进一步证明55穿过外膜并逆转美罗培南的活性。此外，55在体内

  DOI：

  10.1016/j.ejmech.2021.113965
• 作为产物：
  描述：

  N-甲基咪唑 、 氯甲酸乙酯 在 正丁基锂 、 三甲基氯硅烷 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 以37%的产率得到1-甲基-1H-咪唑-2-甲酸乙酯
  参考文献：
  名称：

  一锅顺序溴化和Sonogashira交叉偶联对咪唑的高度区域选择性C-5烷基化

  摘要：

  可通过一锅顺序程序轻松制备各种2取代的5-炔基-1 H-咪唑，该程序涉及1，2-二甲基-1 H-咪唑，2-氯-1的高度区域选择性亲电C-5溴化反应-甲基-1 H-咪唑和2-芳基-1-甲基-1 H-咪唑，然后进行有效的钯/铜共催化的Sonogashira型炔基化反应。

  DOI：

  10.1016/j.tetlet.2015.04.094

文献信息

• [EN] 4(SPIROPIPERIDINYL)METHYL SUBSTITUTED PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] 4(SPIROPIPERIDINYL)METHYL PYRROLIDINES SUBSTITUEES SERVANT DE MODULATEURS DE L'ACTIVITE DES RECEPTEURS DES CHIMIOKINES
  申请人：MERCK & CO INC

  公开号：WO2004058763A1

  公开（公告）日：2004-07-15

  3-Substituted pyrrolidines having a spiropiperidinylmethyl substituent on the 4-position of the ring are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

  在环的4位上具有螺环哌啶甲基取代基的3-取代吡咯烷可用作化学因子受体活性调节剂。具体来说，这些化合物可用作化学因子受体CCR-3和/或CCR-5的调节剂。
• Photocatalytic acyl azolium-promoted alkoxycarbonylation of trifluoroborates
  作者：Joshua L. Zhu、Karl A. Scheidt

  DOI：10.1016/j.tet.2021.132288

  日期：2021.7

  and coupling of organic radical species, the alkoxycarbonyl radical remains underexplored relative to other carbon-containing radical species. Drawing inspiration from new strategies for generating acyl radical equivalents utilizing dual N-heterocyclic carbene catalysis and photocatalysis, we have prepared dimethylimidazolium esters that can function as an alkoxycarbonyl radical surrogate under photocatalytic

  尽管最近在有机自由基物种的选择性产生和偶联方面取得了进展，但相对于其他含碳自由基物种，烷氧羰基自由基仍未得到充分探索。从利用双N-杂环卡宾催化和光催化生成酰基自由基等价物的新策略中汲取灵感，我们制备了可在光催化条件下用作烷氧基羰基自由基替代物的二甲基咪唑鎓酯。我们通过制备由这种自由基替代物与氧化生成的烷基自由基偶联产生的酯，证明了这些基于唑鎓的伙伴的合成效用。
• [EN] NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE 1,3-OXAZOLIDINE ET UTILISATION DE CES DERNIERS COMME INHIBITEURS DE LA RÉNINE
  申请人：NOVADEX PHARMACEUTICALS AB

  公开号：WO2011056126A1

  公开（公告）日：2011-05-12

  The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.

  本发明涉及某些新颖的1,3-噁唑烷化合物（I）的公式，以及制备这类化合物的方法，以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。
• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20070249593A1

  公开（公告）日：2007-10-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I化合物：其中Z、X、J、R2和W在说明书中规定，以及抑制蛋白酪氨酸激酶，尤其是c-fms激酶的溶剂化物、水合物、互变异构体和药用盐。治疗自身免疫病；和治疗具有炎症成分的疾病；治疗来自卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；和治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症性和神经性疼痛；以及骨质疏松症、佩吉特病，以及骨吸收介导病状的其它疾病，包括类风湿性关节炎、其它形式的炎症性关节炎、骨关节炎、假体失败、溶骨肉瘤、骨髓瘤和骨转移瘤，也提供了式I化合物。
• [EN] CATALYST COMPOUNDS<br/>[FR] COMPOSÉS CATALYTIQUES
  申请人：UNIV SHEFFIELD

  公开号：WO2013079942A1

  公开（公告）日：2013-06-06

  The present invention relates to compounds, particularly but not exclusively, compounds for use as catalysts, methods for producing said compounds and the use of said compounds as catalysts in catalytic processes including, but not limited to, the asymmetric reduction of imine and enamine compounds and/or the reductive amination of ketone compounds. The compounds have the formula 1 wherein: R1, R2, R3, R4 and R5 are each separately selected from the group consisting of hydrogen, alkyl and aryl; X is oxygen or sulfur; W is selected from the group consisting of – OR18,–SR18, –NR19R20, –PR19R20 where R18 is alkyl or aryl, and R19 and R20 are each separately selected from the group consisting of hydrogen, alkyl and aryl; and Z has the formula 2 wherein: R6 and R7 are each separately selected from the group consisting of hydrogen, alkoxy, nitro, halogen, alkyl and aryl, or R6 and R7 are linked to form a cyclic group; and Y is oxygen, sulfur or NR10 in which R10 is selected from the group consisting of hydrogen, alkyl and aryl.

  本发明涉及化合物，特别是但不限于用作催化剂的化合物，生产上述化合物的方法以及将上述化合物用作催化剂在催化过程中的使用，包括但不限于对亚胺和烯胺化合物的不对称还原和/或对酮化合物的还原胺化反应。这些化合物的化学式为1，其中：R1、R2、R3、R4和R5分别从氢、烷基和芳基组成的群体中独立选择；X为氧或硫；W从-OR18、-SR18、-NR19R20、-PR19R20组成的群体中选择，其中R18为烷基或芳基，R19和R20分别从氢、烷基和芳基组成的群体中独立选择；Z的化学式为2，其中：R6和R7分别从氢、烷氧基、硝基、卤素、烷基和芳基组成的群体中独立选择，或者R6和R7连接形成一个环状基团；Y为氧、硫或NR10，其中R10从氢、烷基和芳基组成的群体中选择。